171 related articles for article (PubMed ID: 37925144)
1. Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies.
Hansen S; Baastrup Søndergaard M; von Bülow A; Bjerrum AS; Schmid J; Rasmussen LM; Johnsen CR; Ingebrigtsen T; Håkansson KEJ; Johansson SL; Bisgaard M; Assing KD; Hilberg O; Ulrik C; Porsbjerg C
Chest; 2024 Feb; 165(2):253-266. PubMed ID: 37925144
[TBL] [Abstract][Full Text] [Related]
2. Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort.
Milger K; Suhling H; Skowasch D; Holtdirk A; Kneidinger N; Behr J; Timmermann H; Schulz C; Schmidt O; Ehmann R; Hamelmann E; Idzko M; Taube C; Lommatzsch M; Buhl R; Korn S
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2701-2712.e2. PubMed ID: 37301433
[TBL] [Abstract][Full Text] [Related]
3. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.
Menzies-Gow A; Hoyte FL; Price DB; Cohen D; Barker P; Kreindler J; Jison M; Brooks CL; Papeleu P; Katial R
Adv Ther; 2022 May; 39(5):2065-2084. PubMed ID: 35287231
[TBL] [Abstract][Full Text] [Related]
4. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry.
McDowell PJ; McDowell R; Busby J; Eastwood MC; Patel PH; Jackson DJ; Mansur A; Patel M; Burhan H; Doe S; Chaudhuri R; Gore R; Dodd JW; Subramanian D; Brown T; Heaney LG;
Eur Respir J; 2023 Dec; 62(6):. PubMed ID: 37857423
[TBL] [Abstract][Full Text] [Related]
5. Asthma biologics: Real-world effectiveness, impact of switching biologics, and predictors of response.
Abbas F; Georas S; Cai X; Khurana S
Ann Allergy Asthma Immunol; 2021 Dec; 127(6):655-660.e1. PubMed ID: 34481992
[TBL] [Abstract][Full Text] [Related]
6. Severe asthma clinical remission after biologic treatment with anti-IL4/IL13: A real-life experience.
Portacci A; Iorillo I; Quaranta VN; Maselli L; Lulaj E; Buonamico E; Dragonieri S; Carpagnano GE
Respir Med; 2023 Oct; 217():107348. PubMed ID: 37422023
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.
Valverde-Monge M; Sánchez-Carrasco P; Betancor D; Barroso B; Rodrigo-Muñoz JM; Mahillo-Fernández I; Arismendi E; Bobolea I; Cárdaba B; Cruz MJ; Del Pozo V; Domínguez-Ortega J; González-Barcala FJ; Olaguibel JM; Luna-Porta JA; Martínez-Rivera C; Mullol J; Muñoz X; Peleteiro-Pedraza L; Picado Valles C; Plaza V; Quirce S; Rial MJ; Soto-Retes L; Valero A; Sastre J
Arch Bronconeumol; 2024 Jan; 60(1):23-32. PubMed ID: 38042707
[TBL] [Abstract][Full Text] [Related]
8. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients.
Thomas D; McDonald VM; Stevens S; Harvey ES; Baraket M; Bardin P; Bowden JJ; Bowler S; Chien J; Chung LP; Gillman A; Hew M; Hodge S; James A; Jenkins C; Katelaris CH; Katsoulotos GP; Langton D; Lee J; Marks G; Peters M; Radhakrishna N; Reynolds PN; Rimmer J; Sivakumaran P; Upham JW; Wark P; Yang IA; Gibson PG
Allergy; 2024 Feb; 79(2):384-392. PubMed ID: 37632144
[TBL] [Abstract][Full Text] [Related]
9. Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma - First Initiators and Switchers.
Hashimoto S; Kroes JA; Eger KA; Mau Asam PF; Hofstee HB; Bendien SA; Braunstahl GJ; Broeders MEAC; Imming LM; Langeveld B; Maitland-van der Zee AH; Oud KTM; Patberg KW; Smeenk FWJM; Romme EAPM; van Bezouw MJ; van de Ven MJ; van Veen A; van Velzen E; van Veen IHPAA; Weersink EJM; Ten Brinke A; Sont JK; Bel EH;
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2099-2108.e6. PubMed ID: 35487369
[TBL] [Abstract][Full Text] [Related]
10. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry.
Chen W; Tran TN; Sadatsafavi M; Murray R; Wong NCB; Ali N; Ariti C; Bulathsinhala L; Gil EG; FitzGerald JM; Alacqua M; Al-Ahmad M; Altraja A; Al-Lehebi R; Bhutani M; Bjermer L; Bjerrum AS; Bourdin A; von Bülow A; Busby J; Canonica GW; Carter V; Christoff GC; Cosio BG; Costello RW; Fonseca JA; Gibson PG; Yoo KH; Heaney LG; Heffler E; Hew M; Hilberg O; Hoyte F; Iwanaga T; Jackson DJ; Jones RC; Koh MS; Kuna P; Larenas-Linnemann D; Lehmann S; Lehtimäki L; Lyu J; Mahboub B; Maspero J; Menzies-Gow AN; Newell A; Sirena C; Papadopoulos NG; Papaioannou AI; Perez-de-Llano L; Perng Steve DW; Peters M; Pfeffer PE; Porsbjerg CM; Popov TA; Rhee CK; Salvi S; Taillé C; Taube C; Torres-Duque CA; Ulrik C; Ra SW; Wang E; Wechsler ME; Price DB
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2732-2747. PubMed ID: 37301430
[TBL] [Abstract][Full Text] [Related]
11. Biologics for severe asthma and beyond.
Mümmler C; Milger K
Pharmacol Ther; 2023 Dec; 252():108551. PubMed ID: 37907197
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
[TBL] [Abstract][Full Text] [Related]
13. Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use.
Jackson DJ; Burhan H; Menzies-Gow A; Pfeffer P; Nanzer A; Garcia Gil E; Morris T; Tran TN; Hirsch I; Dube S
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1534-1544.e4. PubMed ID: 35202871
[TBL] [Abstract][Full Text] [Related]
14. Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma.
Moore WC; Panettieri RA; Trevor J; Ledford DK; Lugogo N; Soong W; Chipps BE; Carr W; Belton L; Gandhi H; Trudo F; Ambrose CS
Ann Allergy Asthma Immunol; 2020 Sep; 125(3):294-303.e1. PubMed ID: 32304877
[TBL] [Abstract][Full Text] [Related]
15. Biologic use and outcomes among adults with severe asthma treated by US subspecialists.
Panettieri RA; Ledford DK; Chipps BE; Soong W; Lugogo N; Carr W; Mohan A; Carstens D; Genofre E; Trudo F; Ambrose CS
Ann Allergy Asthma Immunol; 2022 Oct; 129(4):467-474.e3. PubMed ID: 35728746
[TBL] [Abstract][Full Text] [Related]
16. Tobacco Exposure and Efficacy of Biologic Therapy in Patients With Severe Asthma: A Nationwide Study From the Danish Severe Asthma Register.
Baastrup Soendergaard M; Hansen S; Bjerrum AS; von Bülow A; Haakansson KEJ; Hilberg O; Ingebrigtsen TS; Johnsen CR; Lock-Johansson S; Makowska Rasmussen L; Schmid JM; Ulrik CS; Porsbjerg C
J Allergy Clin Immunol Pract; 2024 Jan; 12(1):146-155.e5. PubMed ID: 37832820
[TBL] [Abstract][Full Text] [Related]
17. Adherence to Asthma Biologics: Implications for Patient Selection, Step Therapy, and Outcomes.
Maddux JT; Inselman JW; Jeffery MM; Lam RW; Shah ND; Rank MA
Chest; 2021 Mar; 159(3):924-932. PubMed ID: 33558205
[TBL] [Abstract][Full Text] [Related]
18. Biologics for severe asthma-Which, when and why?
Shah PA; Brightling C
Respirology; 2023 Aug; 28(8):709-721. PubMed ID: 37222237
[TBL] [Abstract][Full Text] [Related]
19. [Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS)].
Milger K; Korn S; Feder C; Fuge J; Mühle A; Schütte W; Skowasch D; Timmermann H; Suhling H
Pneumologie; 2023 Apr; 77(4):220-232. PubMed ID: 36796422
[TBL] [Abstract][Full Text] [Related]
20. Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments.
Trevor J; Lugogo N; Carr W; Moore WC; Soong W; Panettieri RA; Desai P; Trudo F; Ambrose CS
Ann Allergy Asthma Immunol; 2021 Nov; 127(5):579-587.e1. PubMed ID: 34273485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
